Clinicians managing multiple myeloma have settled the question of whether measurable residual disease (MRD) status matters. It does. The harder question is: when to test and what intervals should guide the sequence of assessments. This article summarises what published data say about timing and what those intervals mean for clinic operations teams running these programmes.
Two validated methods, one shared operational problem
The International Myeloma Working Group (IMWG) recognises two validated bone marrow MRD assessment methods: next-generation flow cytometry (NGF) and next-generation sequencing (NGS). Both must reach a minimum sensitivity of 1 in 105 nucleated cells. Current guidelines are moving toward a 10-6 threshold for demanding treatment targets, according to the 2024 update on multiple myeloma diagnosis, risk stratification, and management.
NGS reaches sensitivities below 10-6. NGF operates at approximately 2×10-6. Comparisons show high concordance between the two methods, with NGS consistently showing an advantage at the deepest sensitivity levels. The method a lab uses affects which patients test as MRD-negative and, by extension, when a confirming test qualifies as sustained negativity under IMWG criteria. That method choice carries downstream scheduling implications that clinic teams rarely consider when starting a programme.
Both methods require adequate bone marrow sampling. Labs need at least 107 cells per sample to reach guideline sensitivity levels. Sample quality is a workflow variable that operations teams must design into protocols. It won't fix itself in the ordering system.
Monitoring during active treatment
During active induction or consolidation therapy, serum protein electrophoresis (SPEP) and serum free-light chain (sFLC) assay typically run monthly. MRD testing is more resource-intensive. Current practice adds it to that baseline protein monitoring at specific response milestones - typically when a patient reaches very good partial response (VGPR) or better - rather than on a fixed calendar schedule independent of response depth.
Research on how treatments affect myeloma disease burden shows the most clinically meaningful change in disease burden occurs within the first 6 to 12 months of therapy. This supports aligning the first meaningful MRD assessment with the end of induction or the post-transplant consolidation window, not with arbitrary monthly intervals. Current evidence does not support monthly MRD bone marrow biopsies for all patients on induction. Most programmes also cannot sustain that pace.
Post-transplant and maintenance: the 12-month requirement
For patients in complete response after autologous stem cell transplantation (ASCT), the timing of MRD assessment has been studied longitudinally. The EMN02/HO95 trial followed patients in complete remission with serial flow-based MRD measurement. Sustained MRD negativity (not just one negative test) predicts longer progression-free survival, according to the NMSG flow-MRD substudy analysis from the EMN02/HO95 trial.
The IMWG defines sustained MRD negativity as two consecutive negative results at least one year apart, both at the 10-5 threshold. This 12-month interval is a guideline requirement. A patient who tests MRD-negative at month 3 post-ASCT needs a confirming assessment at month 15 or later before the clinical record can document sustained negativity. Programmes often miss this requirement because they don't flag the confirmation window at the time of the first negative result.
The durability question extends beyond the first confirmation. Relapse risk continues even in patients who maintain confirmed MRD negativity over years. Research at the link on how MRD-negative duration predicts long-term progression-free survival confirms this. Sustained MRD negativity is a strong prognostic marker but not a final state. Programmes that stop monitoring after the first confirmed result are capturing only part of the clinical picture.
CAR-T and bispecific therapies: distinct timing windows
T-cell-redirecting therapies create a different monitoring context. Current IMWG guidance for CAR-T therapy recommends bone marrow biopsy at 30 days and again at 90 days post-infusion, with MRD assessment triggered when a patient reaches VGPR or better. The day-30 window may not give adequate information in all patient groups. Current research at the 2024 analysis of MRD testing following T-cell-redirecting therapies continues to examine this question.
The biology drives this early-assessment schedule. These therapies can produce rapid, deep responses or initial responses that convert to positivity within weeks. Testing too early risks a result that doesn't reflect durable disease control. Testing too late risks missing a conversion from negative back to positive that would change a clinical decision. The 30-day and 90-day checkpoints balance these competing risks. They're evidence-based but not settled across all patient groups.
For programmes running CAR-T infusions, the scheduling demand is concrete. The day-30 biopsy falls inside a period when patients may still be managing cytokine-related recovery. Coordinating the biopsy, sample processing for NGF or NGS, and the clinical review within a meaningful window requires structured scheduling infrastructure. Ad-hoc calendar management is where this most often fails.
MRD-guided discontinuation: what the trials show
One important change in myeloma care is moving toward MRD-guided maintenance discontinuation. The MRD2STOP trial, published in Blood Cancer Journal, evaluated whether patients reaching sustained multimodal MRD negativity - confirmed with functional imaging - could safely pause maintenance therapy. The trial shows that MRD-based stopping rules work in structured settings, though thresholds, timing, and imaging requirements differ across protocols.
The MAIA and ALCYONE studies showed that sustained MRD negativity predicted better progression-free survival for patients on daratumumab regimens. See the analysis of sustained MRD negativity in MAIA and ALCYONE for details. These results confirmed the 12-month interval as a minimum before using maintenance discontinuation.
For clinic operations teams, MRD-guided discontinuation is primarily a scheduling and documentation challenge. The programme must record when the first MRD-negative result was obtained, flag the one-year confirmation window, confirm the follow-up bone marrow procedure is scheduled within that window, and route the confirmed result to the treating clinician before the next treatment-review appointment. Programmes that rely on individual clinician memory or scattered calendar notes risk missing documentation.
What clinic operations teams need to manage
MRD monitoring evidence translates into a specific set of scheduling requirements. A myeloma programme running both transplant and CAR-T pathways alongside standard maintenance is tracking at least three distinct interval logics simultaneously:
- Monthly serum protein and sFLC monitoring for patients on active induction or consolidation therapy
- Post-transplant MRD assessment at the end of consolidation, with a minimum 12-month confirmation interval before sustained negativity can be documented under IMWG criteria
- Day-30 and day-90 bone marrow biopsy scheduling for patients post-CAR-T infusion, with MRD assessment triggered at VGPR or better
Manual tracking with paper logs or scattered EHR fields breaks down with this complexity. A confirmation biopsy scheduled at 14 months instead of 12, or a day-90 biopsy missed because a patient transferred to a different centre, affects how the MRD result is interpreted and documented for both the clinical record and any trial reporting requirements.
Structured treatment timeline platforms encode interval rules. This is better than scheduling each appointment separately. The underlying logic is simple calendar arithmetic done consistently at scale. The reason it fails in manual systems is volume and handoffs, not because the logic is complex. See why oncology clinics need treatment timelines, not just calendars for more on this structural issue.
The same principle applies to lab result routing. An NGS-based MRD result that arrives in the lab system but is not automatically linked to the correct monitoring interval in the patient's timeline is incomplete. Clinicians reviewing a myeloma case before a decision-making appointment need the result, the date, the method, the prior result date, and the elapsed interval - ideally in a single view. Converting unstructured lab documents to timeline format is discussed at how AI lab extraction changes clinical routine.
The operational dynamics here are not unique to myeloma. Similar scheduling failures occur in other haematological malignancies. See why lymphoma mid-treatment re-staging intervals slip for those patterns. The structural fixes apply to myeloma MRD confirmation scheduling.
Reading the evidence as a programme-level commitment
MRD monitoring is a structured sequence, not a single test. It connects to treatment phase, response milestones, therapy type, and time since the prior result. The evidence from IMWG criteria, the EMN02/HO95 substudy, the MAIA and ALCYONE analyses, and emerging MRD-guided discontinuation trials all point in the same direction: interval discipline matters as much as the test result itself.
Programmes that reliably schedule, document, and communicate MRD results within their evidence-defined windows will be better positioned as MRD-guided treatment decisions become more routine. That requires structured timelines, automated interval flags, and integrated lab routing. Most myeloma programmes lack this infrastructure now.
Rucja's treatment timeline module tracks MRD assessment windows as structured fields tied to each patient's myeloma care pathway, including first-result date, confirmation interval, and testing method. Try a 30-minute demo. Book a demo.